News

  • 2 August 2018 -

    Key piece identified for slowing a colorectal cancer subtype

    Key piece identified for slowing a colorectal cancer subtype

    Study published in Nature Communications

    Researchers from the Hospital del Mar Medical Research Institute, with the support of IDIBELL and CIBERONC, have discovered that inhibiting the Jagged 1 protein prevents tumour growth in mice. This protein plays a key role in the development of the disease, because it activates the cell signal that allows cancer cells to grow and divide. The discovery leads the way to the development of a therapy for treating this type of pathology in humans, the second leading cause of cancer-related death in Western countries.

    more information

  • July 12, 2018 -

    Hospital del Mar successfully uses deep brain stimulation to treat 4 patients with anorexia nervosa

    Hospital del Mar successfully uses deep brain stimulation to treat 4 patients with anorexia nervosa The centre is a pioneer in Europe in using this type of intervention for treating anorexia nervosa. The project analyses the efficacy and tolerability of this technique. 3 of the 4 cases treated so far have shown a positive response, with no complications either in the surgery or brain stimulation. The operation uses robotic technology, with electrodes being inserted into deep brain areas related to mood, anxiety, and motivation/reward. Neurosurgeons and psychiatrists from the Hospital del Mar are working together on this clinical trial.

    more information

  • March 19th -

    Cognitive function in children with Down's syndrome improved by a compound found in green tea

    Cognitive function in children with Down's syndrome improved by a compound found in green tea Clinical trials involving children are very rare, and even more so when it comes to low-prevalence diseases.

    more information

  • 21 december 2011 -

    Identification of new therapeutic weapons against the most aggressive form of breast cancer: objective of an ambitious investigation project

    Identification of new therapeutic weapons against the most aggressive form of breast cancer: objective of an ambitious investigation project

    Personalized medicine against breast cancer

    Triple-negative breast cancer (Estrogen Receptor-Negative, Progesterone Receptor-Negative, and HER-Negative) is a type of breast cancer with clinical characteristics and specific pathologies that represents a relevant clinic problem, as it affects around 20% of all women with breast cancer, and especially those who are young. On this basis, doctors from the Hospital del Mar and scientists from the IMIM (Institute of Medical Investigation of the Hospital del Mar) and the CRG (Center of Genomic Regulation) have now begun an ambitious project together with Roche Diagnostics to identify new therapeutic targets, as well as biomarkers that are predictive of the clinical evolution of this subtype of cancer.

    more information

Internal campaigns

  • Pla d'igualtat del PSMar
  • Hospitals sense fum
  • Hospitals sostenibles

© 2006 - 2018 Parc de Salut Mar · Legal notice and Privacy Police | Cookie Policy | Accessibility